Anti-CD20 therapy in patients with rheumatoid arthritis: Predictors of response and b cell subset regeneration after repeated treatment

Arthritis and Rheumatism

Volumn 58, Issue 6, 2008, Pages 1566-1575

  Roll, Petra ^a   Dörner, Thomas ^b   Tony, Hans Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD38 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOGLOBULIN D; METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL REGENERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; MALE; MEMORY CELL; MULTIPLE CYCLE TREATMENT; OPEN STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RELAPSE; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTE SUBSETS; BIOLOGICAL MARKERS; FEMALE; HUMANS; IMMUNOGLOBULIN D; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION;

EID: 45349102781     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23473     Document Type: Article

References (30)

1. Sanz I, Anolik JH, Looney RJ. B cell depletion therapy in autoimmune diseases [review]. Front Biosci 2007;1:2546-67.
2. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid arthritis is B cell dependent. J Immunol 2001;167:4710-8.
3. Duddy ME, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 2004;172:3422-7.
4. Roosnek E, Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med 1991;173:487-9.
5. Martin F, Chan AC. Pathogenic roles of B cells in human autoimmunity: insights from the clinic. Immunity 2004;20:517-27.
6. Silverman GJ, Carson DA. Roles of B cells in rheumatoid arthritis [review]. Arthritis Res Ther 2003;Supp 14:S1-6.
7. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
8. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
9. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003;48:2146-54.
10. Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007;66:1259-62.
11. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006;54:2377-86.
12. Mease P, Keystone E, Kaell A, Emery P, St.Clair EW, Dougados M, et al. Recent disease activity affects outcome of second course of rituximab for RA [abstract]. Arthritis Rheum 2006;54 Suppl 9:S236.
13. Emery P, Furst DE, Ferraccioli G, Udell J, van Vollenhoven RF, Rowe K, et al. Long-term efficacy and safety of a repeat treatment course of rituximab in RA patients with an inadequate response to disease-modifying anti-rheumatic drugs [abstract]. Arthritis Rheum 2006;54 Suppl 9:S228.
14. Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 years. Rheumatology (Oxford) 2007;46:626-30.
15. Silverman GJ. Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms [review]. Arthritis Rheum 2006;54:2356-67.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
17. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
18. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
19. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:613-20.
20. Dass S, Rawstron AC, Vital EM, Jain S, Bingham SJ, McGonagle D, et al. Highly sensitive B cell analysis predicts response to rituximab therapy in RA [abstract]. Arthritis Rheum 2006;54 Suppl 9:S832.
21. Weller S, Braun MC, Tan BK, Rosenwald A, Cordier C, Conley ME, et al. Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 2004;104:3647-54.
22. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005;174:817-26.
23. + B cells: memory B cells or "memory" B cells? J Immunol 2007;179:13-9.
24. Leandro MJ, Cooper N, Cambridge G, Ehrenstein MR, Edwards JC. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology (Oxford) 2007;46:29-36.
25. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 2002;206:519-27.
26. Walsh CA, Fearon U, FitzGerald O, Veale DJ, Bresnihan B. Decreased CD20 expression in rheumatoid arthritis synovium following rituximab therapy [abstract]. Arthritis Rheum 2006;54(Suppl 9):4109.
27. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hubert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationship with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006;54:723-32.
28. Anolik J, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 2007;122:139-45.
29. Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007;56:3044-56.
30. Avanzini MA, Locatelli F, Dos Santos C, Maccario R, Lenta E, Oliveri M, et al. B lymphocyte reconstitution after hematopoietic stem cell transplantation: functional immaturity and slow recovery of memory CD27+ B cells. Exp Hematol 2005;33:480-6.